2023-01-012023-12-312023-12-31false01291765VIAMED LIMITED2024-04-24iso4217:GBPxbrli:pure012917652023-01-01012917652023-12-31012917652023-01-012023-12-31012917652022-01-01012917652022-12-31012917652022-01-012022-12-3101291765bus:SmallEntities2023-01-012023-12-3101291765bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3101291765bus:FullAccounts2023-01-012023-12-3101291765bus:PrivateLimitedCompanyLtd2023-01-012023-12-3101291765core:WithinOneYear2023-12-3101291765core:AfterOneYear2023-12-3101291765core:WithinOneYear2022-12-3101291765core:AfterOneYear2022-12-3101291765core:ShareCapital2023-12-3101291765core:SharePremium2023-12-3101291765core:RevaluationReserve2023-12-3101291765core:OtherReservesSubtotal2023-12-3101291765core:RetainedEarningsAccumulatedLosses2023-12-3101291765core:ShareCapital2022-12-3101291765core:SharePremium2022-12-3101291765core:RevaluationReserve2022-12-3101291765core:OtherReservesSubtotal2022-12-3101291765core:RetainedEarningsAccumulatedLosses2022-12-3101291765core:LandBuildings2023-12-3101291765core:PlantMachinery2023-12-3101291765core:Vehicles2023-12-3101291765core:FurnitureFittings2023-12-3101291765core:OfficeEquipment2023-12-3101291765core:NetGoodwill2023-12-3101291765core:IntangibleAssetsOtherThanGoodwill2023-12-3101291765core:ListedExchangeTraded2023-12-3101291765core:UnlistedNon-exchangeTraded2023-12-3101291765core:LandBuildings2022-12-3101291765core:PlantMachinery2022-12-3101291765core:Vehicles2022-12-3101291765core:FurnitureFittings2022-12-3101291765core:OfficeEquipment2022-12-3101291765core:NetGoodwill2022-12-3101291765core:IntangibleAssetsOtherThanGoodwill2022-12-3101291765core:ListedExchangeTraded2022-12-3101291765core:UnlistedNon-exchangeTraded2022-12-3101291765core:LandBuildings2023-01-012023-12-3101291765core:PlantMachinery2023-01-012023-12-3101291765core:Vehicles2023-01-012023-12-3101291765core:FurnitureFittings2023-01-012023-12-3101291765core:OfficeEquipment2023-01-012023-12-3101291765core:NetGoodwill2023-01-012023-12-3101291765core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3101291765core:ListedExchangeTraded2023-01-012023-12-3101291765core:UnlistedNon-exchangeTraded2023-01-012023-12-3101291765core:MoreThanFiveYears2023-01-012023-12-3101291765core:Non-currentFinancialInstruments2023-12-3101291765core:Non-currentFinancialInstruments2022-12-3101291765dpl:CostSales2023-01-012023-12-3101291765dpl:DistributionCosts2023-01-012023-12-3101291765core:LandBuildings2023-01-012023-12-3101291765core:PlantMachinery2023-01-012023-12-3101291765core:Vehicles2023-01-012023-12-3101291765core:FurnitureFittings2023-01-012023-12-3101291765core:OfficeEquipment2023-01-012023-12-3101291765dpl:AdministrativeExpenses2023-01-012023-12-3101291765core:NetGoodwill2023-01-012023-12-3101291765core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3101291765dpl:GroupUndertakings2023-01-012023-12-3101291765dpl:ParticipatingInterests2023-01-012023-12-3101291765dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3101291765core:ListedExchangeTraded2023-01-012023-12-3101291765dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3101291765core:UnlistedNon-exchangeTraded2023-01-012023-12-3101291765dpl:CostSales2022-01-012022-12-3101291765dpl:DistributionCosts2022-01-012022-12-3101291765core:LandBuildings2022-01-012022-12-3101291765core:PlantMachinery2022-01-012022-12-3101291765core:Vehicles2022-01-012022-12-3101291765core:FurnitureFittings2022-01-012022-12-3101291765core:OfficeEquipment2022-01-012022-12-3101291765dpl:AdministrativeExpenses2022-01-012022-12-3101291765core:NetGoodwill2022-01-012022-12-3101291765core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3101291765dpl:GroupUndertakings2022-01-012022-12-3101291765dpl:ParticipatingInterests2022-01-012022-12-3101291765dpl:GroupUndertakingscore:ListedExchangeTraded2022-01-012022-12-3101291765core:ListedExchangeTraded2022-01-012022-12-3101291765dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-01-012022-12-3101291765core:UnlistedNon-exchangeTraded2022-01-012022-12-3101291765core:NetGoodwill2023-12-3101291765core:IntangibleAssetsOtherThanGoodwill2023-12-3101291765core:LandBuildings2023-12-3101291765core:PlantMachinery2023-12-3101291765core:Vehicles2023-12-3101291765core:FurnitureFittings2023-12-3101291765core:OfficeEquipment2023-12-3101291765core:AfterOneYear2023-12-3101291765core:WithinOneYear2023-12-3101291765core:ListedExchangeTraded2023-12-3101291765core:UnlistedNon-exchangeTraded2023-12-3101291765core:ShareCapital2023-12-3101291765core:SharePremium2023-12-3101291765core:RevaluationReserve2023-12-3101291765core:OtherReservesSubtotal2023-12-3101291765core:RetainedEarningsAccumulatedLosses2023-12-3101291765core:NetGoodwill2022-12-3101291765core:IntangibleAssetsOtherThanGoodwill2022-12-3101291765core:LandBuildings2022-12-3101291765core:PlantMachinery2022-12-3101291765core:Vehicles2022-12-3101291765core:FurnitureFittings2022-12-3101291765core:OfficeEquipment2022-12-3101291765core:AfterOneYear2022-12-3101291765core:WithinOneYear2022-12-3101291765core:ListedExchangeTraded2022-12-3101291765core:UnlistedNon-exchangeTraded2022-12-3101291765core:ShareCapital2022-12-3101291765core:SharePremium2022-12-3101291765core:RevaluationReserve2022-12-3101291765core:OtherReservesSubtotal2022-12-3101291765core:RetainedEarningsAccumulatedLosses2022-12-3101291765core:NetGoodwill2022-01-0101291765core:IntangibleAssetsOtherThanGoodwill2022-01-0101291765core:LandBuildings2022-01-0101291765core:PlantMachinery2022-01-0101291765core:Vehicles2022-01-0101291765core:FurnitureFittings2022-01-0101291765core:OfficeEquipment2022-01-0101291765core:AfterOneYear2022-01-0101291765core:WithinOneYear2022-01-0101291765core:ListedExchangeTraded2022-01-0101291765core:UnlistedNon-exchangeTraded2022-01-0101291765core:ShareCapital2022-01-0101291765core:SharePremium2022-01-0101291765core:RevaluationReserve2022-01-0101291765core:OtherReservesSubtotal2022-01-0101291765core:RetainedEarningsAccumulatedLosses2022-01-0101291765core:AfterOneYear2023-01-012023-12-3101291765core:WithinOneYear2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:CostValuation2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3101291765core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3101291765core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3101291765core:Non-currentFinancialInstrumentscore:CostValuation2022-12-3101291765core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-3101291765core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-3101291765core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-3101291765core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-3101291765core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-3101291765core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-3101291765core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-3101291765core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-3101291765bus:Director12023-01-012023-12-3101291765bus:Director22023-01-012023-12-3101291765bus:Director32023-01-012023-12-3101291765bus:Director42023-01-012023-12-31

VIAMED LIMITED

Registered Number
01291765
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2023

VIAMED LIMITED
Company Information
for the year from 1 January 2023 to 31 December 2023

Directors

LAMB, Derek Iain
LAMB, Georgeina Greenfield
LAMB, Helen Jean
NIXON, Stephen Wayne

Company Secretary

LAMB, Helen Jean

Registered Address

15 Station Road
Cross Hills
Keighley
BD20 7DT

Registered Number

01291765 (England and Wales)
VIAMED LIMITED
Statement of Financial Position
31 December 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets314,54015,906
14,54015,906
Current assets
Stocks4708,576614,419
Debtors5855,937861,787
Cash at bank and on hand155,305264,421
1,719,8181,740,627
Creditors amounts falling due within one year6(162,320)(194,370)
Net current assets (liabilities)1,557,4981,546,257
Total assets less current liabilities1,572,0381,562,163
Creditors amounts falling due after one year7-(15,000)
Provisions for liabilities8(2,000)(2,000)
Net assets1,570,0381,545,163
Capital and reserves
Called up share capital100100
Profit and loss account1,569,9381,545,063
Shareholders' funds1,570,0381,545,163
The financial statements were approved and authorised for issue by the Board of Directors on 24 April 2024, and are signed on its behalf by:
LAMB, Helen Jean
Director
Registered Company No. 01291765
VIAMED LIMITED
Notes to the Financial Statements
for the year ended 31 December 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The financial statements have been prepared under the historical cost convention on a going concern basis unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
The directors believe that the company has adequate resources to continue in operational existence for the foreseeable future. The company continues to have the support of the directors, shareholders and creditors and therefore continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and/or the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further obligation. Contributions to defined contribution plans are expensed in the period to which they relate. Amounts not paid are shown in accruals in the Statement of Financial Position. The assets of the plan are held separately from the company in independently administered funds.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to the Income Statement
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows: Plant and machinery - 10% to 33% on cost Office equipment - 33% on cost
Finance leases and hire purchase contracts
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the lease term.
Stocks and work in progress
DO NOT USE inc in bottom note unless bottom note adds no value Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete). At each date of Statement of Financial Position, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete the sale. The impairment loss is recognised immediately in the Income Statement
2.Average number of employees

20232022
Average number of employees during the year2020
3.Tangible fixed assets

Plant & machinery

Office Equipment

Total

£££
Cost or valuation
At 01 January 2332,89755,02087,917
Additions2,5007,79310,293
At 31 December 2335,39762,81398,210
Depreciation and impairment
At 01 January 2330,84841,16372,011
Charge for year2,0269,63311,659
At 31 December 2332,87450,79683,670
Net book value
At 31 December 232,52312,01714,540
At 31 December 222,04913,85715,906
4.Stocks

2023

2022

££
Finished goods708,576614,419
Total708,576614,419
5.Debtors: amounts due within one year

2023

2022

££
Trade debtors / trade receivables155,429225,757
Amounts owed by group undertakings657,091607,091
Other debtors21,149-
Prepayments and accrued income22,26828,939
Total855,937861,787
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
6.Creditors: amounts due within one year

2023

2022

££
Trade creditors / trade payables134,413128,828
Bank borrowings and overdrafts853696
Taxation and social security19,64123,397
Other creditors1,41335,450
Accrued liabilities and deferred income6,0005,999
Total162,320194,370
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Creditors: amounts due after one year

2023

2022

££
Other creditors-15,000
Total-15,000
8.Provisions for liabilities
Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation. Provisions are charged as an expense to profit or loss in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Statement of Financial Position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties. When payments are eventually made, they are charged to the provision carried in the Statement of Financial Position.

2023

2022

££
Net deferred tax liability (asset)2,0002,000
Total2,0002,000
9.Pension commitments
The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £11,624 (2022 - £11,023).
10.Related party transactions
The Company has taken advantage of the exemption contained in Section 33 of FRS 102 "Related Party Disclosures" from disclosing transactions with entities which are part of the group, since 100% of the voting rights in the company are controlled within the group. Included within other creditors, is an amount due to Vandagraph Limited of £Nil (2022 - £50,000), a company in which H Lamb, D Lamb and G G Lamb are directors.
11.Parent-subsidiary relationships
Viamed Limited is a 100% subsidiary of Viamed Properties Limited, a company registered in England and Wales and domiciled in Great Britain. The registered office of Viamed Properties Limited is 15 Station Road, Cross Hills, Keighley, West Yorkshire, BD20 7DT. The financial statements of Viamed Properties Limited are available to the public and may be obtained from The Registrar of Companies, Companies House, Crown Way, Cardiff, CF14 3UZ.